Page 22 Adam • Evaluation of the Humoral/Fc-mediated Immune Responses… Bibliography Ackerman, M. E., Mikhailova, A., Brown, E. P., Dowell, K. G., Walker, B. D., Bailey-Kellogg, C., Suscovich, T. J., & Alter, G. (2016). Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control. PLoS pathogens, 12(1), e1005315. https://doi.org/10.1371/journal.ppat.1005315 Altfeld, M. & Gale, M. (2015). Innate immunity against HIV-1 infection. Nature Immunology, 16(6), 554-562. https://doi.org/10.1038/ni.3157 Baden, L. R., Walsh, S. R., Seamen, M. S., Tucker, R. P., Krause, K. H., Patel, A., Johnson, J. A., Kleinjan, J., Yanosick, K. E., Perry, J., Zablowsky, E., Abbink, P., Peter, L., Iampietro, M. C J., heung, A., Pau, M. G., Weijtens, M., Goudsmit, J., Swann, E., Wolff, M., Loblein, H., Dolin, R., & Barouch D. H. (2013). First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001). The Journal of Infectious Diseases, 207(2), 240-247. https://doi.org/10.1093/infdis/jis670 Baden, L. R.; Stieh, D.J.; Sarnecki, M.; Walsh, S. R.; Tomaras, G. D.; Kublin, J. G.; McElrath, M. J.; Alter, G.; Ferrari, G.; Montefiori, D.; Mann, P.; Nijs, S.; Callewaert, K.; Goepfert, P.; Edupuganti, S.; Karita, E.; Langedijk, J. P.; Wegmann, F.; Corey, L.; Pau M. G.; Barouch, D. H.; Schuitemaker, H.; Tomaka, F. (2020). Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. The Lancet, 7(10), 688-698. https://doi.org/10.1016/S2352-3018(20)30229-0 Barouch, D. H., Stephenson, K. E., Borducchi, E. N., Smith, K., Stanley, K., McNally, A. G., Liu, J., Abbink, P., Maxfield, L. F., Seaman, M. S., Dugast, A. S., Alter, G., Ferguson, M., Li, W., Earl, P. L., Moss, B., Giorgi, E. E., Szinger, J. J., Eller, L. A., Billings, E. A., … Michael, N. L. (2013). Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell, 155(3), 531–539. https://doi.org/10.1016/j.cell.2013.09.061 Barouch, D. H.; Tomaka, F. L.; Wegmann, F.; Stieh, D. J.; Alter, G.; Robb, M. L.; Michael, N. L.; Peter, L.; Nkolola, J. P.; Borducchi, E. N.; Chandrashekar, A.; Jeton, D.; Stephenson, K. L E i . , ; W.; Koerber, B.; Tomaras, G. D.; Montefiori, D. C.; Gray, G.; Frahm, N.; … Schuitemaker, H. (2018). Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomized, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). The Lancet, 392(10143), 232-243. https://doi.org/10.1016/S0140-6736(18)31364-3 Baum, L. L., Cassutt, K. J., Knigge, K., Khattri, R., Margolick, J., Rinaldo, C., Kleeberger, C. A., Nishanian, P., Henrard, D. R., & Phair, J. (1996). HIV-1 gp120-specific
RkJQdWJsaXNoZXIy MTM4ODY=